PT - JOURNAL ARTICLE AU - Jeewandara, Chandima AU - Kamaladasa, Achala AU - Pushpakumara, Pradeep Darshana AU - Jayathilaka, Deshni AU - Abayrathna, Inoka Sepali AU - Danasekara, Saubhagya AU - Guruge, Dinuka AU - Ranasinghe, Thushali AU - Dayarathne, Shashika AU - Pathmanathan, Thilagaraj AU - Somathilaka, Gayasha AU - Madhusanka, Deshan AU - Tanussiya, Shyrar AU - TPJ, Tibutius AU - Kuruppu, Heshan AU - Wijesinghe, Ayesha AU - Thashmi, Nimasha AU - Milroy, Dushantha AU - Nandasena, Achini AU - Sanjeewani, Nilanka AU - Wijayamuni, Ruwan AU - Samaraweera, Sudath AU - Schimanski, Lisa AU - Tan, T.K. AU - Dong, Tao AU - Ogg, Graham S. AU - Townsend, Alain AU - Malavige, Gathsaurie Neelika TI - Antibody and T cell responses to a single dose of the AZD1222/Covishield vaccine in previously SARS-CoV-2 infected and naïve health care workers in Sri Lanka AID - 10.1101/2021.04.09.21255194 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.09.21255194 4099 - http://medrxiv.org/content/early/2021/04/13/2021.04.09.21255194.short 4100 - http://medrxiv.org/content/early/2021/04/13/2021.04.09.21255194.full AB - Background In order to determine the immunogenicity of a single dose of the AZD1222/Covishield vaccine in a real-world situation, we assessed the immunogenicity, in a large cohort of health care workers in Sri Lanka.Methods SARS-CoV-2 antibodies was carried out in 607 naïve and 26 previously infected health care workers (HCWs) 28 to 32 days following a single dose of the vaccine. Haemagglutination test (HAT) for antibodies to the receptor binding domain (RBD) of the wild type virus, B.1.1.7, B.1.351 and the surrogate neutralization assay (sVNT) was carried out in 69 naïve and 26 previously infected individuals. Spike protein (pools S1 and S2) specific T cell responses were measured by ex vivo ELISpot IFNγ assays in 76 individuals.Results 92.9% of previously naive HCWs seroconverted to a single dose of the vaccine, irrespective of age and gender; and ACE2 blocking antibodies were detected in 67/69 (97.1%) previously naïve vaccine recipients. Although high levels of antibodies were found to the RBD of the wild type virus, the titres for B.1.1.7 and B.1.351 were lower in previously naïve HCWs. Ex vivo T cell responses were observed to S1 in 63.9% HCWs and S2 in 31.9%. The ACE2 blocking titres measured by the sVNT significantly increased (p<0.0001) from a median of 54.1 to 97.9 % of inhibition, in previously infected HCWs and antibodies to the RBD for the variants B.1.1.7 and B.1.351 also significantly increased.Discussion a single dose of the AZD1222/Covishield vaccine was shown to be highly immunogenic in previously naïve individuals inducing antibody levels greater than following natural infection. In infected individuals, a single dose induced very high levels of ACE2 blocking antibodies and antibodies to RBDs of SARS-CoV-2 variants of concern.Funding We are grateful to the World Health Organization, UK Medical Research Council and the Foreign and Commonwealth Office.Competing Interest StatementGNM is in the National Medicinal Regulatory Authority on the expert advisory panel in COVID-19 vaccines. SS in the Chief Epidemiologist in Sri Lanka and is involved in deciding vaccine priority lists.Funding StatementWe are grateful to the World Health Organization, UK Medical Research Council and the Foreign and Commonwealth Office for support. T.K.T. is funded by the Townsend-Jeantet Charitable Trust (charity number 1011770) and the EPA Cephalosporin Early Career Researcher Fund. A.T. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Ethics Review Committee of University of Sri Jayewardenepura.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript and figures.